BDRX

Biodexa Pharmaceuticals plc ADR (BDRX) | Rumor.io

Biodexa Pharmaceuticals

BDRX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,172

Bullish sentiment (50-day avg)80%

Price to earnings ratio0

Market capitalization699.8K

Earnings per share-33.7

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-6.4M

Social

What share of all stock conversation is about BDRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 16

$BDRX has shown a massive volume increase, with a clean breakout from its base, sealing momentum.
The stock's RSI has curled up, and it has lit up the chart, indicating a potential uptrend.
Biodexa Pharmaceuticals' stock price has experienced a significant increase, with some investors making substantial profits, while others have lost money due to the stock's volatility.

Generated by AI

Sentiment

Of the messages about BDRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +36.36	80.79% +9.37	87.09% +3.96
Bearish	—	0% -36.36	19.21% -9.37	12.91% -3.96

Bullish· Sep 15

$BDRX is primed for a short squeeze, with shorts trying to manipulate the price.
Biodexa Pharmaceuticals Plc's warrant exercise agreement is expected to bring in $2.3M in gross proceeds, a significant influx of capital that could fuel further growth.
The stock has shown explosive momentum, with a 100% jump in a single day, and is expected to continue its multi-day run.

Bearish· Sep 15

Biodexa Pharmaceuticals Plc's stock has been on a significant decline, with some investors suggesting it may drop below $2.
The company has a history of dilution, with a 1-for-1 million share ratio since 2019, and is expected to have another reverse stock split soon.
High-interest rates and fees for short-selling positions make it expensive to hold short positions, with some investors facing costs of over 900% on their borrow fees.

Generated by AI

Topics

Of the messages about BDRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	11.61%	35.82%
Technical Analysis	—	—	42.9%	35.39%
Analysts	—	—	32.58%	17.7%
Controversies	—	—	0.65%	0.21%
Macro	—	—	12.26%	10.87%
Earnings	—	—	0%	0%

Announcements· Apr 2

Biodexa Pharmaceuticals (BDRX) has partnered with Syngene International to manufacture MTX240 GMP clinical trial supplies, covering both the active ingredient and dosage form.
This partnership will ensure the production of MTX240 for clinical studies, and BDRX has also launched a global early access program for FAP patients with Tanner Pharma Group.
BDRX's stock is rising following the announcement, with the company's market value potentially increasing due to the partnership with Syngene International.

Technical Analysis· May 22

$BDRX is considered a high squeezability stock, which may have contributed to its price movement.
The stock's VWAP (volume-weighted average price) was broken, which could be a potential entry point for traders.
The support level at $2.00 is holding, and the stock's resistance levels are being closely watched by traders.

Generated by AI

Community

Of the messages about BDRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	16.67%	66.67%	28.77%	44.46%
Newcomers	83.33%	33.33%	71.23%	55.54%

Regulars· Sep 16

The regulars believe that the price action in $BDRX was largely due to the activities of a single entity known as "Armistice" which caused the price to pump above their cost base.
The asset's chart is characterized by massive volume and a clean breakout from the base, which has sealed the momentum, and the RSI has curled up, indicating a strong uptrend.
The regulars are concerned about the asset's volatility, with some predicting a potential 200% move before 6am, and others experiencing significant losses, including one individual who claims to have lost 20K.

Newcomers· Sep 16

Many newcomers are holding onto $BDRX, expecting a significant price increase.
Some are questioning the company's performance, comparing its past prices and expressing skepticism about its potential.
New investors are analyzing the company's prospects, discussing the possibility of high volatility and the need to be cautious about their expectations.

Generated by AI

Today's interview with Stephen Stamp, CEO of (NASDAQ:BDRX) is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower GI tract for which the only current remedy is surgical removal of the colon and/or rectum.Key takeaways: eRapa is an oral drug candidate designed to reduce or eliminate the need for surgical treatments; a Phase 3 registrational trial, running at 29 U.

7d agoYahoo Finance

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

15d agoBenzinga

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,2

15d agoYahoo Finance UK

Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

16d agobenzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

18d agoBenzinga

Biodexa passes halfway mark in Phase 3 trial recruitment for FAP

1mo agoInvesting.com

Also Discussed

Investors talking about BDRX also mention

#	Name	Attention
1	Adicet Bio, Inc. Common StockACET	0%-0.01
2	Bio-Path Holdings Inc.BPTH	0%0
3	Invesco High Income Trust IIVLT	0%0
4	Semilux International Ltd.SELX	0%new
5	ABIO - ARCA biopharma, Inc.	——
6	Eltek Ltd.ELTK	0%new
7	Immunic, Inc.IMUX	0%0
8	MFH - Mercurity Fintech Holding Inc.	——
9	Akari Therapeutics Plc ADRAKTX	0%0
10	Palisade Bio Inc.PALI	0%new

Biodexa Pharmaceuticals plc ADR

Healthcare
Biotechnology

Biodexa Pharmaceuticals plc ADR is the American depositary receipt for Biodexa Pharmaceuticals plc, a clinical-stage biopharmaceutical company focused on developing treatments for diseases with unmet medical needs. The company’s current pipeline targets rare and difficult-to-treat conditions, including familial adenomatous polyposis, non-muscle invasive bladder cancer, type 1 diabetes, and rare brain cancers. Its portfolio includes product candidates and drug-delivery programs designed to improve how therapies are administered and to address areas where existing treatment options remain limited. Biodexa Pharmaceuticals plc ADR represents the company’s U.S.-traded equity interest and provides access to a business centered on specialty pharmaceuticals and innovative medicines. Headquartered in Cardiff, United Kingdom, Biodexa Pharmaceuticals plc operates within the global biotechnology sector, where it plays a niche role in early-stage drug development for underserved patient populations.

Website

Location

1 Caspian Point

Cardiff, CF10 4DQ

United Kingdom

Social

What share of all stock conversation is about BDRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 16

$BDRX has shown a massive volume increase, with a clean breakout from its base, sealing momentum.
The stock's RSI has curled up, and it has lit up the chart, indicating a potential uptrend.
Biodexa Pharmaceuticals' stock price has experienced a significant increase, with some investors making substantial profits, while others have lost money due to the stock's volatility.

Generated by AI

Sentiment

Of the messages about BDRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +36.36	80.79% +9.37	87.09% +3.96
Bearish	—	0% -36.36	19.21% -9.37	12.91% -3.96

Bullish· Sep 15

$BDRX is primed for a short squeeze, with shorts trying to manipulate the price.
Biodexa Pharmaceuticals Plc's warrant exercise agreement is expected to bring in $2.3M in gross proceeds, a significant influx of capital that could fuel further growth.
The stock has shown explosive momentum, with a 100% jump in a single day, and is expected to continue its multi-day run.

Bearish· Sep 15

Biodexa Pharmaceuticals Plc's stock has been on a significant decline, with some investors suggesting it may drop below $2.
The company has a history of dilution, with a 1-for-1 million share ratio since 2019, and is expected to have another reverse stock split soon.
High-interest rates and fees for short-selling positions make it expensive to hold short positions, with some investors facing costs of over 900% on their borrow fees.

Generated by AI

Topics

Of the messages about BDRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	11.61%	35.82%
Technical Analysis	—	—	42.9%	35.39%
Analysts	—	—	32.58%	17.7%
Controversies	—	—	0.65%	0.21%
Macro	—	—	12.26%	10.87%
Earnings	—	—	0%	0%

Announcements· Apr 2

Biodexa Pharmaceuticals (BDRX) has partnered with Syngene International to manufacture MTX240 GMP clinical trial supplies, covering both the active ingredient and dosage form.
This partnership will ensure the production of MTX240 for clinical studies, and BDRX has also launched a global early access program for FAP patients with Tanner Pharma Group.
BDRX's stock is rising following the announcement, with the company's market value potentially increasing due to the partnership with Syngene International.

Technical Analysis· May 22

$BDRX is considered a high squeezability stock, which may have contributed to its price movement.
The stock's VWAP (volume-weighted average price) was broken, which could be a potential entry point for traders.
The support level at $2.00 is holding, and the stock's resistance levels are being closely watched by traders.

Generated by AI

Community

Of the messages about BDRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	16.67%	66.67%	28.77%	44.46%
Newcomers	83.33%	33.33%	71.23%	55.54%

Regulars· Sep 16

The regulars believe that the price action in $BDRX was largely due to the activities of a single entity known as "Armistice" which caused the price to pump above their cost base.
The asset's chart is characterized by massive volume and a clean breakout from the base, which has sealed the momentum, and the RSI has curled up, indicating a strong uptrend.
The regulars are concerned about the asset's volatility, with some predicting a potential 200% move before 6am, and others experiencing significant losses, including one individual who claims to have lost 20K.

Newcomers· Sep 16

Many newcomers are holding onto $BDRX, expecting a significant price increase.
Some are questioning the company's performance, comparing its past prices and expressing skepticism about its potential.
New investors are analyzing the company's prospects, discussing the possibility of high volatility and the need to be cautious about their expectations.

Generated by AI

Biodexa Pharmaceuticals

Social

Sep 16

Bullish· Sep 15

Bearish· Sep 15

Announcements· Apr 2

Technical Analysis· May 22

Regulars· Sep 16

Newcomers· Sep 16

The Longview: Fireside Chat with Biodexa CEO Stephen Stamp

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

12 Health Care Stocks Moving In Friday's Intraday Session

Biodexa passes halfway mark in Phase 3 trial recruitment for FAP

Also Discussed

Biodexa Pharmaceuticals plc ADR

Company Information

Location

The Longview: Fireside Chat with Biodexa CEO Stephen Stamp

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

12 Health Care Stocks Moving In Friday's Intraday Session

Biodexa passes halfway mark in Phase 3 trial recruitment for FAP

Also Discussed

Social

Sep 16

Bullish· Sep 15

Bearish· Sep 15

Announcements· Apr 2

Technical Analysis· May 22

Regulars· Sep 16

Newcomers· Sep 16